This firm's average rating is Buy from 3 analysts.
Our recommendation tool can cross-verify current
analyst consensus on Yield10 Bioscience and to analyze the firm potential to grow in the current economic cycle.
What is the right price you would pay to acquire a share of Yield10 Bioscience? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
Watch out for price decline
Please consider monitoring Yield10 Bioscience on a daily basis if you are holding a position in it. Yield10 Bioscience is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Yield10 Bioscience stock to be traded above the $1 level to remain listed. If Yield10 Bioscience stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
What is happening with Yield10 Bioscience this year
Annual and quarterly reports issued by Yield10 Bioscience are formal
financial statements that are published yearly and quarterly and sent to Yield10 stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Yield10 Bioscience often view their annual report as an effective marketing tool to disseminate their perspective on company
future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Yield10 Bioscience Gross Profit
Yield10 Bioscience Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Yield10 Bioscience previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Yield10 Bioscience Gross Profit growth over the last 10 years. Please check Yield10 Bioscience's
gross profit and other
fundamental indicators for more details.
Is Yield10 a risky opportunity?
Let's check the volatility. Yield10 is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Yield10 (NASDAQ:YTEN) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. picking up a share of a Yield10 Bioscience stock makes you a part-owner of that company.
Yield10 Bioscience Current Consensus
Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering Yield10 Bioscience. The Yield10 consensus assessment is calculated by taking the average estimates from all of the analysts covering Yield10 Bioscience
| Strong Buy | 2 | 66.67 |
| Buy | 1 | 33.33 |
| Hold | 0 | 0.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Are Yield10 Bioscience technical ratios showing a correction?
The maximum drawdown is down to 33.62 as of today. Yield10 Bioscience is displaying above-average volatility over the selected time horizon. Investors should scrutinize Yield10 Bioscience independently to ensure intended market timing strategies are aligned with expectations about Yield10 Bioscience volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Yield10 Bioscience's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Yield10 Bioscience's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Conclusion on Yield10 Bioscience
Whereas many other companies in the agricultural inputs industry are either recovering or due for a correction, Yield10 may not be as strong as the others in terms of longer-term growth potentials. To conclude, as of the 7th of May 2021, our analysis shows that Yield10 Bioscience hyperactively responds to market trends. The company is
undervalued and projects
very high probability of financial unrest for the next 2 years. Our current 90 days advice on the company is
Cautious Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Yield10 Bioscience. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
